Crucell, GSK sign agreement to develop 'second generation malaria vaccine'

Crucell, the Dutch biotechnology company, "said on Tuesday it had agreed with Britain's GlaxoSmithKline [GSK] to jointly develop a malaria vaccine candidate, without disclosing financial details," Reuters reports (Gray-Block, 4/6).

In a press release, Crucell said it signed a "binding letter of agreement" with GSK "to collaborate on developing a second generation malaria vaccine candidate" (4/6). According to Reuters, the agreement is an extension of a 2003 partnership between the two companies and the Walter Reed Army Institute of Research that focused on evaluating "Crucell's malaria vaccine candidate in pre-clinical studies."

"Crucell said on Tuesday pre-clinical data indicated greatly enhanced immune responses against the malaria parasite when Crucell's Adenovirus [AdVac] technology and GSK's RTS,S/AS technology are used in combination, versus either component alone," the news service writes. Crucell and GSK plan to start human trials and will look for additional funding from another source to move forward with clinical trials in the U.S. "Pending the results of the trial, the companies expect to advance the candidate in further clinical studies with the support of public or non-profit partners," Reuters reports (4/6).

"Malaria currently represents one of the most prevalent infections in tropical and subtropical areas, causing close to 900,000 deaths every year, mostly amongst children," Ronald Brus, Crucell's CEO, said in the press release. "I am confident a partnership of this kind will allow us to take a vital step towards our goal of bringing meaningful innovation to global health" (4/6).

Kaisernetwork.orgThis article is republished with kind permission from our friends at The Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of health policy developments, debates and discussions. The Kaiser Daily Health Policy Report is published for, a free service of The Henry J. Kaiser Family Foundation. Copyright 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy